Kura Oncology (NASDAQ:KURA) Stock Price Up 8% on Analyst Upgrade

Kura Oncology, Inc. (NASDAQ:KURA)’s stock price traded up 8% during mid-day trading on Friday after Wedbush raised their price target on the stock from $36.00 to $38.00. Wedbush currently has an outperform rating on the stock. Kura Oncology traded as high as $10.87 and last traded at $10.90. 858,721 shares changed hands during trading, a decline of 45% from the average daily volume of 1,565,944 shares. The stock had previously closed at $10.09.

Other equities research analysts also recently issued reports about the company. CLSA set a $24.00 price objective on Kura Oncology in a report on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a report on Friday, July 17th. Wall Street Zen upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Sanford C. Bernstein set a $24.00 price objective on shares of Kura Oncology in a report on Monday, June 15th. Finally, Citizens Jmp restated a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, June 15th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $25.62.

Insider Buying and Selling

In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of Kura Oncology stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total transaction of $834,002.78. Following the transaction, the insider owned 182,345 shares of the company’s stock, valued at $1,790,627.90. The trade was a 31.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 7.60% of the company’s stock.

Key Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: Second-quarter results exceeded expectations. Kura reported a loss of $0.77 per share versus the consensus estimate of a $0.88 loss, while revenue of $20.87 million topped expectations of $20.16 million. Kura Oncology Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: KOMZIFTI® momentum improved. The drug generated $9.1 million in net product revenue, up 57% from the first quarter, with approximately 115 new patient starts, a 35% sequential increase. This provides evidence of growing commercial adoption. Kura Oncology Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management outlined meaningful future revenue potential. Kura expects $90 million–$110 million of collaboration revenue in 2027 and is targeting topline results from the KOMET-017 study in 2028, giving investors additional development and revenue milestones to track. Kura Outlines 2027 Collaboration Revenue and 2028 KOMET-017 Results
• Positive Sentiment: Wedbush raised its price target to $38 from $36 and maintained an “outperform” rating, signaling substantial potential upside based on the firm’s view of Kura’s prospects. Wedbush Raises Kura Oncology Price Target
• Neutral Sentiment: Analyst sentiment is mixed, with recent coverage highlighting conflicting views on Kura’s outlook and the latest clinical evidence. This may contribute to elevated volatility as investors assess trial data and commercialization progress. Analysts Have Conflicting Sentiments on Kura Oncology
• Negative Sentiment: Brookline Capital Markets lowered its FY2029 EPS estimate to $5.70 from $6.01. Kura also continues to report substantial losses, underscoring its dependence on product growth, collaboration revenue and successful clinical development. Kura Oncology Analyst Estimate Update

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds have recently made changes to their positions in KURA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Kura Oncology by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after purchasing an additional 2,977 shares during the period. Strs Ohio purchased a new stake in Kura Oncology during the 1st quarter valued at approximately $143,000. Legal & General Group Plc raised its position in shares of Kura Oncology by 35.1% during the second quarter. Legal & General Group Plc now owns 72,910 shares of the company’s stock valued at $421,000 after buying an additional 18,930 shares during the last quarter. Rhumbline Advisers raised its position in shares of Kura Oncology by 13.0% during the second quarter. Rhumbline Advisers now owns 118,896 shares of the company’s stock valued at $686,000 after buying an additional 13,690 shares during the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Kura Oncology by 244.5% in the second quarter. American Century Companies Inc. now owns 232,752 shares of the company’s stock worth $1,343,000 after buying an additional 165,189 shares in the last quarter.

Kura Oncology Trading Up 8.0%

The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14. The stock’s 50-day moving average is $10.17 and its two-hundred day moving average is $9.32. The stock has a market cap of $967.59 million, a P/E ratio of -3.23 and a beta of 0.38.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.11. The company had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $20.16 million. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 169.73%. Equities research analysts anticipate that Kura Oncology, Inc. will post -3.45 EPS for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.